Engineering of HIV-1 neutralizing antibody CAP256V2LS for manufacturability and improved half life

[1]  N. Doria-Rose,et al.  Analytical characterization of broadly neutralizing antibody CAP256LS heavy chain clipping during manufacturing development , 2022, Biotechnology progress.

[2]  Bradford W Tippett,et al.  Tyrosine O-sulfation proteoforms affect HIV-1 monoclonal antibody potency , 2022, Scientific Reports.

[3]  D. Montefiori,et al.  Broadly neutralizing monoclonal antibodies for HIV prevention , 2021, Journal of the International AIDS Society.

[4]  Allan C. deCamp,et al.  Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. , 2021, The New England journal of medicine.

[5]  J. Mascola,et al.  A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention , 2021, mAbs.

[6]  J. Mascola,et al.  Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial , 2020, BMJ Open.

[7]  J. Mascola,et al.  Structure of Super-Potent Antibody CAP256-VRC26.25 in Complex with HIV-1 Envelope Reveals a Combined Mode of Trimer-Apex Recognition. , 2020, Cell reports.

[8]  T. Limjindaporn,et al.  Serine Protease Inhibitor AEBSF Reduces Dengue Virus Infection via Decreased Cholesterol Synthesis. , 2019, Virus research.

[9]  J. Mascola,et al.  Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial. , 2019, The lancet. HIV.

[10]  Jacob Demirji,et al.  Development of an alternating tangential flow (ATF) perfusion‐based transient gene expression (TGE) bioprocess for universal influenza vaccine , 2019, Biotechnology progress.

[11]  Vera B. Ivleva,et al.  Characterization of AEBSF-antibody modifications for a protease inhibitor supplementation strategy , 2019, Analytical and Bioanalytical Chemistry.

[12]  A. Casablancas,et al.  A new strategy for fed-batch process control of HEK293 cell cultures based on alkali buffer addition monitoring: comparison with O.U.R. dynamic method , 2018, Applied Microbiology and Biotechnology.

[13]  Vera B. Ivleva,et al.  Investigation of Sequence Clipping and Structural Heterogeneity of an HIV Broadly Neutralizing Antibody by a Comprehensive LC-MS Analysis , 2018, Journal of The American Society for Mass Spectrometry.

[14]  J. Mascola,et al.  Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults , 2018, PLoS medicine.

[15]  M. Andersen,et al.  Fed-Batch CHO Cell Culture for Lab-Scale Antibody Production. , 2018, Methods in molecular biology.

[16]  B. Korber,et al.  Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge , 2017, Science Translational Medicine.

[17]  Denise M O'Hara,et al.  Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies , 2016, mAbs.

[18]  C. Soto,et al.  Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody , 2016, Science.

[19]  Lynn Morris,et al.  Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection , 2016, PLoS pathogens.

[20]  Lynn Morris,et al.  New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency , 2015, Journal of Virology.

[21]  Lynn Morris,et al.  Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies , 2015, Nature Medicine.

[22]  M. Oka,et al.  Dendritic cells transfected with heat-shock protein 70 messenger RNA for patients with hepatitis C virus-related hepatocellular carcinoma: a phase 1 dose escalation clinical trial , 2015, Cancer Immunology, Immunotherapy.

[23]  Zexian Liu,et al.  Systematic analysis of the in situ crosstalk of tyrosine modifications reveals no additional natural selection on multiply modified residues , 2014, Scientific Reports.

[24]  Jason Condon,et al.  Understanding and modeling alternating tangential flow filtration for perfusion cell culture , 2014, Biotechnology progress.

[25]  Young Do Kwon,et al.  Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection against Lentiviral Infection In Vivo , 2014, Journal of Virology.

[26]  Hongmei Gao,et al.  Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. , 2014, Journal of immunological methods.

[27]  R. Ionescu,et al.  Fragmentation of monoclonal antibodies , 2011, mAbs.

[28]  G. A. Lazar,et al.  Enhanced antibody half-life improves in vivo activity , 2010, Nature Biotechnology.